全球首款磷吸收抑制剂万缇乐在中国获批上市

南方财经网
26 Feb

  南方财经2月26日电,复星医药(股票代码:600196.SH;02196.HK)宣布,控股子公司上海复星医药产业发展有限公司(“复星医药产业”)获独家开发和商业化许可的全新机制降磷创新药盐酸替那帕诺片(中国境内商品名:万缇乐®)用于控制对磷结合剂疗效不充分或不耐受的慢性肾脏病(CKD)成人透析患者的血清磷水平的药品注册申请于近日获国家药品监督管理局(NMPA)批准上市。作为全球首个且目前唯一获批的磷吸收抑制剂,此次万缇乐®在中国正式获批,开启了多种机制协同降磷的新时代。(21世纪经济报道)

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10